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the CDR antibodies partially recovered CB immunoreac-
tivity, suggesting a transient structural change in CB cal-
cium-binding site. We discovered that CDR2 and CB co-
immunoprecipitate. Furthermore, the expression levels of 
voltage-gated calcium channel Cav2.1, protein kinase C 
gamma and calcium-dependent protease, calpain-2, were 
increased after CDR antibody internalization. Inhibition 
of these signaling pathways prevented or attenuated CDR 
antibody-induced CB and L7/Pcp-2 immunoreactivity loss, 
morphological changes and increased protein expression. 
These results signify that CDR antibody internalization 
causes dysregulation of cell calcium homeostasis. Hence, 
drugs that modulate these events may represent novel neu-
roprotective therapies that limit the damaging effects of 
CDR antibodies and prevent PC neurodegeneration.
Keywords Calbindin D28K · Calcium homeostasis · 
Paraneoplastic cerebellar degeneration · Onconeural Yo 
antibodies · Purkinje cell death · Purkinje cell-specific 
protein-2
Abbreviations
Abs  Antibodies
AMPA  α-Amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid
Ca2+  Calcium ion
CB  Calcium-binding protein calbindin D28K
CDR  Cerebellar degeneration-related protein
cOTSC  Cerebellar organotypic slice culture
IgG  Immunoglobulin G
L7/Pcp-2  Purkinje cell-specific protein-2
PC  Purkinje cell
PCD  Paraneoplastic cerebellar degeneration
PKC  Protein kinase C
VGCC  Voltage-gated calcium channel
Abstract Paraneoplastic cerebellar degeneration (PCD) 
is characterized by loss of Purkinje cells (PCs) associated 
with progressive pancerebellar dysfunction in the presence 
of onconeural Yo antibodies. These antibodies recognize 
the cerebellar degeneration-related antigens CDR2 and 
CDR2L. Response to PCD therapy is disappointing due 
to limited understanding of the neuropathological mecha-
nisms. Here, we report the pathological role of CDR anti-
bodies on the calcium homeostasis in PCs. We developed 
an antibody-mediated PCD model based on co-incubation 
of cerebellar organotypic slice culture with human patient 
serum or rabbit CDR2 and CDR2L antibodies. The CDR 
antibody-induced pathology was investigated by high-
resolution multiphoton imaging and biochemical analy-
sis. Both human and rabbit CDR antibodies were rapidly 
internalized by PCs and led to reduced immunoreactivity 
of calbindin D28K (CB) and L7/Pcp-2 as well as reduced 
dendritic arborizations in the remaining PCs. Washout of 
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Introduction
Paraneoplastic cerebellar degeneration (PCD), caused 
by Purkinje cell (PC) death in the cerebellum, is a para-
neoplastic neurological disorder with severe pancerebellar 
symptoms, such as ataxia, nystagmus, and dysarthria [72]. 
Cross-reactivity of onconeuronal Yo antibodies (Yo Abs) 
and T cells with antigens in the tumor tissue and cerebel-
lum induce PCD [63]. Yo Abs bind to the cytoplasmic anti-
gen of cerebellar degeneration-related protein 2 (CDR2, 
50 kDa, RefSeq NM_001802.1) and 2-like (CDR2L, 
62 kDa, RefSeq NM_014603.2) and are found in the serum 
and cerebrospinal fluid of patients with remote, non-meta-
static ovarian and breast cancers [7, 22, 72].
Brain, normal ovary tissue, and tumor tissue express 
CDR2 protein [15, 30, 70]. CDR2 interacts with proteins 
involved in signal transduction and gene transcription such 
as: cell cycle-related proteins; PKN, a fatty acid-activated 
serine/threonine protein kinase; and c-myc [48, 49, 54, 55, 
66]. CDR2L has ~50 % sequence identity with CDR2, but 
is not expressed in PCD tumor tissue [15]. In the cerebel-
lum, both CDR2 and CDR2L proteins are present in the 
cytoplasm and proximal dendrites of PCs, but their func-
tions are unknown [15, 49, 52].
The PCs are the sole projection neurons in the cerebel-
lum and therefore proper morphological as well as physi-
ological integrity of the PC dendrites is essential for cer-
ebellar function [25, 67]. Optimal intracellular Ca2+ levels 
and Ca2+ flux via cytoplasmic Ca2+-binding protein cal-
bindin D28K (CB) and the GoLoco domain protein, Purkinje 
cell-specific protein-2 (L7/Pcp-2), are essential for cellu-
lar and molecular mechanisms involved in neurotransmit-
ter release, ion channel permeability, enzyme activity, and 
gene transcription [6, 24, 39, 57]. With its four Ca2+-bind-
ing sites, CB is a Ca2+ buffer and sensor; it regulates fast 
Ca2+ influx by Ca2+ binding [57] and is considered as a 
PC survival marker [28, 38]. L7/Pcp-2 modulates P/Q-type 
voltage-gated calcium channels’ (VGCC) function, whose 
dysfunction is implicated in ataxia [27, 39, 69]. Factors that 
modulate or disrupt CB and L7/Pcp-2 are expected to exert 
powerful physiological and pathological effects on PCs and 
are listed in Table S1.
In the present study, an ex vivo model of rat cerebellar 
organotypic slice culture (cOTSC) was used to study the 
neuropathological mechanisms underlying the antibody-
mediated PCD and to identify potential intracellular treat-
ment targets which are elaborated in Table S1. Multiphoton 
imaging showed that CDR2 and CDR2L antibody internali-
zation reduced the CB and L7/Pcp-2 immunoreactivity lev-
els in PCs. This antibody-driven immunoreactivity loss was 
reduced by modifying the intracellular Ca2+ transients and 
inhibiting the Ca2+-dependent protease calpain (Table 1). 
These findings suggest that widespread consequences of 
Ca2+ homeostasis dysregulation can induce morphological 
changes and fatal alterations in the cell signaling pathways, 
thereby causing neurodegeneration.
Materials and methods
Patients’ sera
We used four female patients’ sera that were antibody posi-
tive for CDR2 (hCDR2+(PS1)), CDR2L (hCDR2L+(PS2)) or 
both CDR2 and CDR2L (hCDR2/2L+(PS3/PS4)) [22] and 
negative for P/Q-type VGCC (RIA; DLD Diagnostika, 
#RA006/12). Patient data are listed in Table S2. The sera 
were collected before treatment took place and stored at 
−80 °C at the Paraneoplastic Neurological Diseases Bio-
bank (#484) with the approval of the Regional Committee 
for Medical and Health Research Ethics in Western Nor-
way, Diagnostic markers of cancer (188.05). As control 
serum, we pooled samples from 100 healthy blood donors 
without any known autoimmune disease (non-hCDR).
Cerebellar organotypic slice culture (cOTSC)
All procedures were performed according to the National 
Institutes of Health Guidelines for the Care and Use of 
Laboratory Animals Norway (FOTS 20135149/20113133). 
To prepare cOTSC, we used 152 Wistar Hannover GLAST 
rat pups (in-house breeding colony), age P10–P15. Fol-
lowing anesthesia and decapitation, we transferred the cer-
ebellum into ice-cold EBSS solution (Gibco, #24010043) 
containing 0.5 % D-glucose (Sigma, #G8769) and 10 mM 
HEPES (Gibco, #15630056). Four to five cerebellar par-
asagittal slices (400 μm thick) were cut on NVSLM1 
motorized advance vibroslice (WPI) and transferred 
individually onto 0.4 μm pore size membranes (Milli-
cell, Millipore, # PICMO1250). Slices were maintained 
in 24-well plates at the air/culture media interface con-
sisting of 30 % advanced DMEM/F12 solution (Gibco, 
#126340010), 20 % MEM solution (Gibco, #41090028), 
25 % EBSS solution, 25 % heat-inactivated horse serum 
(Sigma, #H1138), 1 mM l-glutamine (Gibco, #35050038), 
5 mg/mL d-glucose, and 2 % B-27 serum-free supplement 
(Gibco, #17504044), and incubated with 5 % CO2 at 35 °C 
(Fig. 1a). The culture medium was removed and replaced 
24 h post-slicing (100 %) and then every 2nd day (75 %). 
The slices recovered for 7 days before treatment.
Antibody-mediated PCD model: patients’ sera (hCDR) 
and polyclonal affinity-purified rabbit antibodies (rCDR)
hCDR and rCDR were heat inactivated (56 °C, 30 min) to 
destroy complement factors prior to treatment to obtain 
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neutral IgG antibody assays and added at various concen-
trations to the cOTSC media for 2–6 days (Fig. 1b). We 
used human sera hCDR2+, hCDR2L+, and hCDR2/2L+, 
non-hCDR at dilutions of 1:250, 1:500, and 1:1000, 
and affinity-purified polyclonal rabbit antibody rCDR2 
(Sigma, #HPA023870), rCDR2L (Sigma, #HPA022015), 
or both (1:1 mixture) and rIgG (Millipore, #12370) in 
total concentrations of 20, 40, 125, or 400 ng/mL. Each 
independent experiment (n ≥ 3) included positive and 
negative controls to avoid variations in immunoreac-
tivity to the applied hCDR and rCDR between each 
experiment.
Neuropharmacology
The following drugs were used: MDL28170 a potent, 
selective inhibitor of calpain (Ki = 10 nM; Tocris, #1146); 
CNQX an AMPA receptor antagonist (IC50 = 1–2 μM; 
Tocris, #1045); ω-agatoxin a selective and reversible 
blocker of Cav2.1 (P/Q-type VGCC) (Alomone, #A-530); 
K252a a non-selective protein kinase inhibitor that inhib-
its PKC (IC50 = 32.9 nM; Tocris, #1683); U0126 a selec-
tive non-competitive inhibitor of MEK-1 and MEK-2 
(IC50 = 60–70 nM; Tocris, #1144).
Primary antibodies
The antibodies used in immunohistochemical (IHC), West-
ern blot (WB), and immunoprecipitation (IP) analyses are 
detailed in Table S3.
Immunohistochemistry
cOTSC sections
After treatment, cOTSC were washed with pre-warmed 
0.1 M PBS (1xPBS; Gibco, #70013016) and fixed (4 % 
paraformaldehyde (PFA)/0.5 % sucrose in PBS, pH 7.2; 
4 h, 4 °C). Slices were quenched with PBS/50 mM NH4Cl 
(PBSN), permeabilized with PBSN/1 % Triton X-100 
(60 min, 22 °C), rinsed (3 × 5 min) with PBSN, and incu-
bated in primary Ab against calbindin D28K, caspase-3, 
or L7/Pcp-2 for 2 days at 4 °C in PBSN containing 5 % 
bovine serum albumin (BSA; Sigma, #A2153), 0.2 % Tri-
ton X-100 (Sigma, #T9284), and 100 μM glycine (Sigma, 
#G7126). The slices were washed (3 × 5 min) with PBSN 
and incubated with 2nd Ab (Alexa Fluor® 488/594 Don-
key Anti-Mouse and/or Donkey Anti-Rabbit IgG (H + L), 
1:500; Molecular Probes, #A21202, #A21203, #A21204, 
or # A21207) for 2 days at 4 °C in PBSN/2.5 % BSA. Slices 
were rinsed (3 × 5 min) with PBSN and mounted with Pro-
moFluor Antifade Reagent (Promokine, #PK-PF-AFR1). 
The slices from each experiment were stained simultane-
ously to minimize variations in immunoreactivity of pri-
mary and 2nd Ab solution within the investigated groups.
Cryostat sections
Anesthetized adult female rats were transcardially perfused 
with ice-cold 4 % PFA–PBS. The brains were post-fixed 
(24 h, 4 °C), incubated in 18 % sucrose–PBS (72 h, 4 °C), 
snap-frozen, and cut on a cryostat into 8 μm parasagittal 
sections. Sections were air dried (30 min, 22 °C), blocked 
in PBS/0.2 % BSA/1 % Triton X-100 (PBSB, 2 h, 22 °C), 
incubated in patient serum (PBSB/patient serum, overnight, 
4 °C, 1:2000), rinsed (3 × 5 min) with PBS, incubated with 
2nd Ab (PBSB/Alexa Fluor® 488 Goat Anti-Human IgG 
(H + L), 1:500, # A11013, Molecular Probes, 2 h, 22 °C), 
rinsed (3 × 5 min) with PBS, and mounted with Prolong-
Gold Antifade Reagent (Invitrogen, #P36931). Slices were 
scanned with a DM6000 CFS-TCS SP5 confocal micro-
scope (Leica).
Paraffin‑embedded sections
Six days after hCDR2/2L and non-hCDR internalization, 
slices were fixed (4 % PFA), embedded in paraffin, sliced 
into 4 µm thick sections, and stained with hematoxylin and 
a b
c
Fig. 1  CDR antibody-mediated PCD model. a Ex-vivo PCD model 
system of cerebellar organotypic slice culture (cOTSC). b Experi-
mental design used to investigate the CDR antibody pathology on 
cerebellar PC physiology. h/rCDR were added to the culture media 
of cOTSC 7 days after preparation (treatment, red arrow). Pathologi-
cal effects of the administered treatment were analyzed 2, 4, and 6 
days later by immunohistochemistry (IHC) and Western blot analy-
sis (WB). The reversibility of the observed CDR-induced pathology 
was tested by IHC at 2, 4, and 7 days after 6 days of CDR treatment 
(washout). c Multiphoton micrographs were collected, and PC were 
counted on three to eight scans of 0.056 mm³ for each treated cOTSC 
slice to determine the effects of CDR treatment
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eosin (HE). Images of the HE stain sections were taken 
with a 40 × 0.65 air objective on Leica DMLS with Axi-
oCam MRC (Zenlite 2011, Zeis) at 100 ms exposure time.
Multiphoton imaging
Multiphoton images were collected with a Ti Sapp laser 
(Coherent Chameleon Ultra2) and DM6000 CFS-TCS 
SP5 microscope (Leica) using an HCX PL APO 20 × 1.0 
water-immersion objective (with a digital zoom of ×1.7 
or ×3.0 [Fig. 3b]). Excitation was performed at 740 nm 
(6.8–7.2 mW laser power); emission was detected for 
Alexa Fluor® 488/594 with the NDD1/NDD2 external 
detectors, respectively. The fluorescence intensity was 
adjusted to 75 % of the maximum in untreated controls for 
each experiment. Z-stack images were taken at 0.5–1 μm 
intervals. Pictures were superimposed using LASAF soft-
ware version 2.5.1 (Leica Microsystems CMS GmbH). 
Additionally, images from Alexa Fluor® 488/594 Don-
key Anti-Mouse IgG staining in Figs. 2b, 3b, c, h were 
pseudo-colored in gray and inverted for clarity using Fiji. 
Figure S1b was created as 3D projections with orthogo-
nal section from z-stacks using the Fiji plug-in 3D Viewer. 
Calbindin D28K (CB+)- and L7/Pcp-2 (L7/Pcp-2+)-positive 
PCs were counted manually and automatically, but blind in 
three to eight images of 750 × 750 × 100 μm in each slice 
for each experiment (nE) and group and projected to mm3 
(Fig. 1c). The automatic count was performed with Fiji: (1) 
image → stack → plug-in: z projection [max intensity]; 
(2.) image → adjustment → plug-in: auto threshold [yen]; 
(3) analyze → plug-in: 3D objects counter [threshold: 50; 
size filter: min: 200 and max: 1000]. The manual and auto-
matic counts produced equivalent numbers.
Western blot analysis
The treated cOTSC were washed with pre-warmed 1xPBS 
(pH 7.4) and sonicated in ice-cold lysis buffer (in mM: 50 
Tris–HCl (pH 7.5), 150 KCl, 1 DTT, 1 PMFS, 0.1 % NP40, 
1 % SDS, and complete protease inhibitor cocktail (Roche, 
#1187380001)). The lysates (40 μg) were subjected to gradi-
ent SDS-PAGE under reducing conditions (15–4 % Tris TGX 
gels; Bio-Rad, #456-1086), transferred onto PVDF membrane 
(0.2 μm pore size; Bio-Rad, #162-0177) and incubated over-
night (4 °C) with anti-calbindin D28K, anti-calpain-1, anti-cal-
pain-2, anti-Cav2.1, anti-PKCγ, and anti-β-tubulin. The blots 
were developed using horseradish peroxidase-conjugated 2nd 
Ab (polyclonal Swine Anti-Rabbit IgG-HRP, Dako, #P0217; 
Goat Anti-Mouse IgG-HRP, Santa Cruz Biotechnology Inc., 
#SC-2500; 90 min, 22 °C) and the Pierce ECL chemilumines-
cence system (Thermo Fisher Scientific Inc., #3210634075). 
Semi-quantitative densitometry analysis was performed 
(Bio-Rad, Quantity One 4.6.6). For each sample, the protein 
level was normalized to β-tubulin and expressed relative to 
untreated naive control, set at 1 (arbitrary units).
Protein complex immunoprecipitation (Co-IP)
Co-IP was performed with rat cerebellar tissue. The tis-
sue was homogenized by 10–15 strokes in a Dounce-type 
glass homogenizer (buffer in mM: 20 Tris–HCl (pH 7.4), 
137 NaCl, 10 % glycerol, 1 EDTA, 1 PMSF, 1 DTT, 1 % 
NP-40, protease inhibitors). Homogenates were centrifuged 
(13,000g, 4 °C, 10 min) and the supernatants were used for 
immunoprecipitation after pre-clearing with protein G mag-
netic beads (1 h, 4 °C; Millipore, # LSKMAGG02). The 
supernatants were incubated with 2 μg/mL of specific Ab 
with constant agitation (overnight, 4 °C). A further 40 μL 
of fresh protein G magnetic beads was added and incu-
bated for 1 h at 4 °C. The beads were washed three times (IP 
buffer in mM: 50 Tris–HCl (pH 7.4), 150 NaCl, 1 EDTA, 1 
PMSF, 1 DTT, 0.1 % NP-40, protease inhibitors) and incu-
bated with 100 mM dithiothreitol and 2× Laemmli sample 
buffer (5 min, 95 °C). Eluted proteins were resolved by SDS-
PAGE. We immunoprecipitated against: anti-CDR2, anti-
CDR2L, anti-Cav2.1, and anti-calbindin D28k (2 μg).
Data analysis and statistics
Data analysis and calculations were performed using the 
software Excel 2003 and Graph Pad Prism 4.0. Data are 
presented as mean ± SEM, and statistical significance was 
determined using the non-parametric two-tailed paired 
Mann–Whitney’s U test. The level of significance is indi-
cated with asterisks: *p < 0.05; **p < 0.01; ***p < 0.001.
Results
Calbindin D28K (CB) function is modified by hCDR 
and rCDR antibodies
We investigated four female patients’ sera that were posi-
tive for CDR2, CDR2L, or both CDR2/2L and negative for 
P/Q-type VGCC (Table S2). Cerebellum cryostat sections 
incubated with those human patients’ sera (hCDR; 1:2000) 
confirmed that hCDRs bound to PCs. hCDR2/2L+(PS3/
PS4)
 showed stronger PC binding than hCDR2+(PS1) and 
hCDR2L+(PS2) (Fig. 2a).
To evaluate the pathological effects of hCDR internali-
zation into PCs in the absence of the lymphatic system 
and blood–brain barrier, we applied the sera to cOTSC 
(Fig. 1a). We collected samples at different time points and 
studied PC survival by counting CB-positive PCs in mul-
tiphoton micrographs (Fig. 1b, c) [28, 38]. To exclude Ab 
diffusion into dead PCs with permeable membranes, we 
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performed control monoclonal anti-CB staining without 
Triton X-100 in the incubation buffers. We did not find 
false-positive CB immunoreactivity (data not shown).
hCDR internalization significantly reduced the num-
ber of CB-positive PCs (CB+-PCs) over time (nE = 4; 
Fig. 2c, d; Table 1). The remaining CB+-PCs showed 
reduced dendritic arborizations (Fig. 2b). Within 48 h, 
CB+-PC loss was significantly higher in hCDR2L+(PS2) 
than hCDR2+(PS1) (*p = 0.0373; Fig. 2c), but did not dif-
fer between hCDR2/2L+(PS3) and hCDR2/2L+(PS1+PS2) and 
was most strongly pronounced in hCDR2/2L+(PS4) (Fig. 2d; 
Table 1). Compared to the non-hCDR control, more than 
70 % of CB+-PCs were lost at day 6 of hCDR internaliza-
tion (***p < 0.0001; Fig. 2c, d; Table 1).
To elucidate whether the observed pathology was 
induced by CDR antibodies, we treated the cOTSC with 
heat-inactivated affinity-purified polyclonal rabbit Abs 
against CDR2 (rCDR2+) and CDR2L (rCDR2L+), or both 
(1:1 mixture, rCDR2/2L). We found that within 6 days both 
rCDR2 and rCDR2L were internalized and led to exten-
sive loss of CB staining (400 ng/mL; Fig. 3a, merged). We 
observed three patterns of CB immunoreactivity modifica-
tions after rCDR treatment: (1) whole cell staining with 
neighboring cells unstained, (2) dendritic staining with only 
a weak remaining signal in the soma, and (3) soma staining 
with no dendritic staining (Fig. 3b). The remaining CB+-
PCs showed morphological alterations in their dendritic 
arborizations with a loss of tertiary branches (Fig. 3c).
To verify the progression of rCDR-induced PCD-like 
pathology, samples were collected at different time points 
(nE = 4; 400 ng/mL; Fig. 3c, d). We found no effect on the 
number of CB+-PCs in rIgG control. Meanwhile within 
48 h, we observed that rCDR treatment caused a 50–60 % 
CB+-PCs loss. The CB+-PC loss under rCDR2/2L and 
rCDR2L was of similar magnitude, but significantly 
greater than in rCDR2 (nE = 4, *p = 0.0369; Fig. 3d; 
Table 1). rCDR reduced CB+-PCs by ~80 % within 
6 days (rCDR groups compared to rIgG+ ***p < 0.0001; 
Fig. 3d; Table 1). The progression of the antibody-driven 
loss of CB in the first 48 h was similar in rCDR2 and 
rCDR2L compared to hCDR2+(PS1) and hCDR2L+(PS2) 
(Table 1).
To study antibody level effects, we tested four rCDR 
concentrations (ng/mL): 400, 125, 40, and 20 (nE = 3, 
4 days). We found a reduction of CB+-PCs by ~80 % (400 
and 125 ng/mL), 60 % (40 ng/mL), and 40 % (20 ng/mL) 
compared to rIgG control (***p < 0.0001; Fig. 3e) with no 
difference between rCDR2 and rCDR2L.
The Western blot analysis of rCDR-treated cOTSC 
lysates (6 days, 125 ng/mL) showed no effect on CB pro-
tein concentration compared to untreated naive control 
(nE = 10; Fig. 3f, g). It is therefore likely that the reduced 
CB immunoreactivity is caused by structural modifications 
of the CB Ca2+-binding site or misfolding of the protein 
itself [11, 50]. To investigate this hypothesis, we replaced 
the rCDR-containing media (125 ng/mL, 6 days) with non-
CDR media (Fig. 1b, washout, 7 days). The number of 
CB+-PCs in rIgG control was not affected by washout or 
by time (Fig. 3h, i). We found that the washout of rCDR 
improved the CB+-PC count in rCDR2L and rCDR2/2L 
-treated cOTSC within 48 h (D2wo) (rCDR2: p = 0.1383, 
rCDR2L: **p = 0.0018, rCDR2/2L: **p = 0.0010; 
Fig. 3i). All rCDR groups showed substantial recovery of 
CB+-PCs at day 7 after washout (***p < 0.0001; Fig. 3h, 
i; Table 1), but plateaued between days 4 and 7 at ~ 40 % 
CB+-PC loss before reaching the rIgG control count. This 
supports our hypothesis that the CB Ca2+-binding epitope 
is reversibly altered or blocked, or that the protein might be 
misfolded.
To analyze whether CDR proteins and CB interact at 
physiological expression levels, we assayed by recipro-
cal co-immunoprecipitation (Co-IP) CDR2, CDR2L, and 
CB proteins from cerebellar lysates. As shown in Fig. 4a, 
b, CB and CDR2 specifically Co-IPed, indicating endog-
enous CDR2–CB complex in PCs. Interestingly, CDR2L 
did not form any complex with CB (anti-CDR2L from 
three sources), but showed strong CDR2 Co-IP (Fig. 4a, c). 
These Co-IP results suggest that CDR2 antibody can sub-
stantially influence CB function by binding to an interact-
ing protein.
Although CB immunoreactivity was reduced after hCDR 
and rCDR internalization, the micrographs in Fig. 3a 
showed no cell loss. HE staining of hCDR2/2L+(PS3)-treated 
cOTSC (1 μL/mL, 6 days) showed normal cytoarchitecture 
and no distinct loss of PCs (Fig. S1a). Furthermore, stain-
ing for the apoptotic marker of active cleaved caspase-3 in 
rCDR2/2L-treated cOTSC (100 ng/mL, 6 days) showed 
small scattered cleaved caspase-3-positive apoptotic cells 
which did not co-localize with CB+-PCs (Fig. S1b). This 
caspase-3 staining profile was not different from the rIgG 
control.
GoLoco domain protein L7/Pcp-2 is affected by hCDR 
and rCDR antibodies
PCs express GoLoco domain protein L7/Pcp-2, which 
interacts with Gαo and Gαi proteins and thereby modu-
late the P/Q-type VGCC (Cav2.1) functions in a concen-
tration-dependent manner [39]. The P/Q-type is the major 
VGCC in PCs and linked to ataxia pathogenesis [27, 69]. 
To evaluate whether L7/Pcp-2 is influenced by CDR inter-
nalization, we stained hCDR- and rCDR-treated cOTSC 
against L7/Pcp-2. The L7/Pcp-2 positive (L7/Pcp-2+) PC 
loss was similar to the observed CB+-PC loss (Fig. S2; 
Table 1). Both hCDR (1 μL/mL) and rCDR (100 ng/mL) 
induced L7/Pcp-2+-PC loss of more than 65 % (6 days, 
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hCDR nE = 3; rCDR nE = 4; compared to rIgG control 
***p < 0.0001; Fig. S2a–d; Table 1).
This suggests that another important Ca2+ homeostasis 
regulator is affected by CDR antibody internalization.
VGCC Cav2.1 is up-regulated by hCDR and rCDR 
antibodies
To confirm the suggested interaction of L7/Pcp-2 and 
Cav2.1, we performed Co-IPs on rat cerebellum extract 
and confirmed the protein complex (Fig. 5a). As a conse-
quence of this interaction, the CDR antibody-induced loss 
of L7/Pcp-2 might influence the VGCC protein expres-
sion. To test whether VGCCs are affected by CDR inter-
nalization, we performed Western blot analysis of rCDR-
treated cOTSC. We found that rCDR internalization 
increased the protein expression of Cav2.1 by more than 
twofold (100 ng/mL, 6 days, all groups compared to rIgG 
controls, ***p < 0.0001; Fig. 5b, c) and co-treatment with 
VGCC antagonist ω-agatoxin (150 nM) blocked this effect 
(Fig. 5g, h; #p < 0.005; nE = 6). ω-agatoxin co-treatment 
averted CB+- and L7/Pcp-2+-PC loss (Fig. 5d–f). The 
rescue of CB and L7/Pcp-2 immunoreactivity was most 
strongly pronounced in rCDR2/2L+/ω-agatoxin co-treated 
cOTSC (***p < 0.0001, 6 days; nE = 5; Fig. 5e, f; Table 1). 
ω-Agatoxin at 150 nM did not affect the CB+- and L7/
Pcp-2+-PC count or Cav2.1 protein expression in rIgG and 
untreated naive controls.
Inactivation of VGCC by blocking AMPA receptor-
mediated synaptic depolarization with AMPA recep-
tor antagonist CNQX revealed a similar rescue of 
CB+- and L7/Pcp-2+-PC loss (Fig. 6a–e; Table 1). We 
found that co-treatment of hCDR2/2L+(PS3) (1 μL/
mL) with CNQX minimized the CB+-PC loss signifi-
cantly in a concentration-dependent manner (CNQX: 
44 ± 8 % (5 μM), 24 ± 8 % (10 μM), 14 ± 6 % (25 μM); 
Fig. 2  Calbindin D28K immuno-
reactivity loss in Purkinje cells 
in response to experimental 
induced human CDR antibody-
mediated PCD. a Human CDR 
(hCDR)/PC binding was visual-
ized by anti-human IgG AF488 
staining of 8 μm cryostat rat 
cerebellum sections incubated 
with hCDR+ patients’ sera 
(1:2000). Magnification of the 
conducted cerebellar PC region 
micrographs (lower panel) 
shows that both hCDR2 and 
hCDR2L antibodies bound to 
the PC soma. Scale bars 25 μm. 
b Multiphoton micrographs of 
cOTSCs: Independent of the Ab 
target, all hCDR sera  
(4 μL/mL; 6 days; PS1-4)  
led to CB-positive (CB+) PC 
loss and altered their dentritic 
morphology; scale bars 40 μm. 
c, d Calculation of  CB+ cells/
mm3 after 2, 4, and 6 days of 
hCDR internalization revealed 
pathological effects of  hCDR 
compared to non-hCDR control 
over time (nE = 4). Data in 
mean ± SEM. Non-parametric 
two-tailed paired Mann–
Whitney’s U test. *p < 0.05; 
**p < 0.01; ***p < 0.001. The 
percentage changes to controls 
are summarized in Table 1
a
c
b
d
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***p < 0.0001, 6 days; nE = 6; Fig. 6b). Similar CB+- 
and L7/Pcp-2+-PC loss reduction was obtained under 
10 μM CNQX/hCDR2/2L+(PS4) co-treatment (1 μL/mL 
hCDR2/2L+(PS4); ***p < 0.0001; 6 days; nE = 4; Fig. 6b, 
c; Table 1). The CDR-specific effects of CNQX (10 μM) 
were also tested with rCDR2 and rCDR2L (100 ng/mL, 
a b
c d
e f g
h i
Fig. 3  Affinity-purified rabbit CDR-Abs (rCDR) reduce calbindin 
D28K immunoreactivity in a time- and concentration-dependent 
manner with partial recovery after CDR-Ab washout. a rCDR2 and 
rCDR2L (400 ng/mL, 6D) are independently internalized into PCs 
(green). Only few CDR-marked cells (arrow) are positively cor-
related with calbindin D28K (CB, magenta); scale bars 20 μm. We 
found different expression patterns of CB immunoreactivity and PC 
morphology modifications for rCDR2 b, rCDR2L, and rCDR2/2L 
compared to rIgG control (c); scale bars 40 μm. The CB immuno-
reactivity loss, studied 2, 4, and 6 days of rCDR internalization by 
stereological counting of CB+ cells/mm3, was time- (d) and con-
centration- (e) dependent (time: nE = 4; concentration: nE = 3). f, 
g Western blot analysis of rCDR-treated cOTSC lysate (125 ng/
mL, D6) showed no difference in CB protein levels to rIgG controls 
(nE = 10). h CB+-PC immunoreactivity loss at day 6 of rCDR inter-
nalization was partially rescued 7 days (D7wo) post-rCDR washout 
(scale bars 40 μm), but did not reach control level and plateaued 
between washout days 4 and 7 (nE = 3) (i). Data in mean ± SEM. 
Non-parametric two-tailed paired Mann–Whitney’s U test. *p < 0.05; 
**p < 0.01; ***p < 0.001. Table 1: CDR-Ab effects in percentage
843Acta Neuropathol (2014) 128:835–852 
1 3
6 days). rCDR/CNQX co-treatment partially rescued CB+-
PCs (***p = 0.0001; nE = 6; Fig. 6d; Table 1), with bet-
ter rescue in rCDR2L/CNQX (63 %) than rCDR2/CNQX 
(38 %) (**p = 0.0054). The L7/Pcp-2+-PC count in co-
treated rCDR2 or rCDR2L cOTSC with 10 μM CNQX 
showed reduction of L7/Pcp-2+-PC loss to 48 ± 3 % 
(rCDR2/CNQX) and 27 ± 5 % (rCDR2L/CNQX), respec-
tively (***p < 0.0001; 6 days; nE = 4; Fig. 6e; Table 1). 
The CNQX co-treatment was more beneficial for rCDR2L 
than for rCDR2, as seen with CB staining (L7/Pcp-2+-PC 
rescue: 30 % (CDR2) vs. 60 % (CDR2L), **p = 0.0011). 
The number of CB+- and L7/Pcp-2+-PCs in the rIgG con-
trol was not affected by the AMPA receptor antagonist.
Taken together, these data show that reducing Ca2+ 
influx through VGCC mitigates the CDR antibody-induced 
pathology by lowering intracellular Ca2+ levels.
PKCγ is up-regulated by CDR2 and CDR2/2L antibodies
The postsynaptic Ca2+ transient can be modulated by 
inhibition of Ca2+-activated phospholipid-dependent pro-
tein kinase C (PKC) activity to prevent AMPA receptor-
mediated synaptic depolarization [19, 73]. PKC is asso-
ciated with apoptosis in cerebellar ischemia and stroke 
[8]. Missense mutations in PKCγ gene cause spinocer-
ebellar ataxia type 14 [58, 60]. We found that 6 days 
of rCDR2 and rCDR2/2L internalization significantly 
increased PKCγ protein expression (rCDR2: 1.43 ± 0.12, 
**p = 0.0079; rCDR2/2L: 1.62 ± 0.29, *p = 0.0250; 
Fig. 7a, b), but not rCDR2L (1.23 ± 0.18, p = 0.1810; 
Fig. 7b). Therefore, we co-administrated 50 nM K252a to 
inhibit PKC activity during CDR internalizations. Block-
ing PKC activity with K252a prevented CDR antibody-
induced CB+- or L7/Pcp-2+ -PC (hCDR2/2L+(PS3)[1 μL/
mL]; 6 days; ***p < 0.0001; nE = 4; and rCDR [125 ng/
mL]; ***p < 0.0001; 6 days; nE = 4; Fig. 7c–f; Table 1) 
and blocked the increased PKCγ protein expression 
caused by rCDR2 and rCDR2/2L internalization (Fig. 7g, 
h; #p < 0.003; nE = 6). rCDR2L internalization had no 
effect on PKCγ protein expression, while CB+- and L7/
Pcp-2+-PC loss was rescued by K252a co-treatment in the 
rCDR2L group. The antagonist had no effect on the CB+- 
or L7/Pcp-2+ count or PKCγ protein expression in the rIgG 
and untreated naive control.
The results show that the CDR antibody-mediated 
pathology can be attenuated in the presence of VGCC, 
AMPA receptor, and PKC signaling inhibition.
Ca2+-dependent protease calpain-2 is activated by CDR 
antibody internalization
Changes in VGCC, AMPA receptor, and PKC signaling can 
lead to elevated intracellular Ca2+ levels and induce Ca2+-
dependent proteases activity. To examine whether CDR 
internalization affects Ca2+-dependent proteases activity of 
calpain-1 and calpain-2, we performed Western blot analy-
sis of rCDR-treated cOTSC lysates. Calpain-1 expression 
was not affected, but calpain-2 expression was significantly 
increased (rCDR2: 2.05 ± 0.14, ***p < 0.0001; rCDR2L: 
1.72 ± 0.14, ***p = 0.0002; rCDR2/2L: 1.84 ± 0.19, 
**p = 0.0012; 125 ng/mL; 6 days; Fig. 8a–c). We then 
investigated whether calpain-2 over-activation/-expression 
a b c
Fig. 4  CB Co-IPed with CDR2 but not with CDR2L. a, b, c cerebel-
lar lysates were subjected to co-immunoprecipitation (co-IP) with 
anti-CDR2, -CDR2L, or -CB Abs, and the precipitated proteins (IP) 
were immunoblotted with CDR2, CDR2L, and CB (Co-IP). The blots 
consist of four lanes: input (1 % rat cerebellar lysates), beads + rIgG 
(lysates with 2 μg of species-specific IgG), unbound (1 % super-
natant after IP with specific antibody) and IP (Protein complexes 
recovered after Co-IP with specific antibody as indicated in the fig-
ure). Arrowheads: probed protein and nonspecific IgG* (heavy chain, 
55 kDa). Left: molecular mass markers (kDa). Western blots of pro-
teins recovered after IP of the CDR2 complex a showed that CB and 
CDR2L interact with CDR2, which was endorsed by reciprocally 
Co-IP (b, c). However, CDR2L was not Co-IPed with CB (b)
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could be antagonized by calpain-specific inhibitor 
MDL28170, a known neuroprotective substrate in ischemia 
and traumatic injury models [9, 36]. MDL28170 co-
application with hCDR2/2L+(PS3/PS4) (6 days) reduced the 
CB+-PC loss to ~45 %, as well as the CDR-induced pathol-
ogy on the dendritic arborizations in the remaining PCs 
(nE = 6 for PS3 and nE = 4 for PS4; Fig. 8d, e; Table 1). 
We found no difference between the 10 (42 ± 9 %) and 
a b
c
d
e f
g
h
Fig. 5  VGCC Cav2.1 expression is up-regulated by CDR-Ab inter-
nalization. a  Rat cerebellar lysates were Co-IPed with anti-Cav2.1 
and then detected by anti-L7/Pcp-2 in Western blot. Cav2.1 Co-IPed 
with L7/Pcp-2 (left panel) and IPed itself (control, right panel). 
Arrowheads: probed protein and nonspecific IgG* (heavy chain, 
55 kDa). Left: molecular mass markers (kDa). Pathology of 125 ng/
mL rCDR after 6 days correlated to VGCC. b Representative West-
ern blot: Cav2.1 expression after rCDR treatment; c rCDR internali-
zation induces twofold rise in Cav2.1 expression level (nE = 19), d 
z-stack multiphoton micrographs: co-application of Cav2.1 antago-
nist ω-agatoxin (150 nM) prevents rCDR2/2L induced loss of CB+ 
(magenta) and L7/Pcp-2+ (green) PCs; scale bars 40 μm. Stereologi-
cal counting of CB+ (e) and L7/Pcp-2+ (f) cells/mm3 supported the 
observed neuroprotective effect of ω-agatoxin during rCDR internali-
zation for all tested groups (nE = 7). g Representative Western blot: 
Cav2.1 expression after rCDR/ω-agatoxin co-treatment; h ω-agatoxin 
co-treatment blocks the rCDR-induced increase in Cav2.1 expres-
sion (nE = 7). Data are mean ± SEM. Non-parametric two-tailed 
paired Mann–Whitney’s U test. *p < 0.05; **p < 0.01; ***p < 0.001; 
#p < 0.005; Table 1: CDR antibody effects in percentage
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20 μM (44 ± 7 %) MDL28170/hCDR2/2L+(PS3) treatment 
(p = 0.3841; Fig. 8e; Table 1). The MDL28170-induced 
rescue of CB+-PCs differed between hCDR2/2L+(PS4) 
(18 %) and hCDR2/2L+(PS3) (48 %) (*p = 0.0207; 10 μM; 
Fig. 8e; Table 1). Furthermore, hCDR2/2L+(PS4)-induced 
L7/Pcp-2+-PC loss was partially rescued by 10 μM 
MDL28170 (***p < 0.0001; nE = 3; Fig. 8f; Table 1). 
MDL28170 (10 μM) co-treatment of rCDR2, rCDR2L, and 
rCDR2/2L-treated cOTSC (125 ng/mL, 6 days) showed an 
improvement of the dendritic morphology and significant 
reduction of CB+-PC loss (***p < 0.0001; nE = 5; Fig. 8g; 
Table 1). The increase of calpain-2 expression seen during 
CDR internalization was blocked by 10 μM MDL28170 
(Fig. 8h, i; #p < 0.008; nE = 6).
These data show that CDR internalization leads to an 
increase in intracellular unbound Ca2+ to the millimolar 
range, which thereby activate the Ca2+-dependent protease 
calpain 2.
MAP kinase signaling is not affected by CDR antibody 
internalization
Activation of mitogen-activated protein (MAP) kinase 
signaling cascades are associated with PKC-depend-
ent synaptic depression/declustering of glutamate 
receptors, inflammation, death receptor activation, 
apoptosis, and oxidative stress [12, 23, 35]. Co-treat-
ment of cOTSC with hCDR2/2L+ (1 μL/mL, 6 days) 
and MAP kinase inhibitor U0126 (5 μM) did not pre-
vent the CB+- or L7/Pcp-2+-PC immunoreactivity loss 
(CB: hCDR2/2L+(PS3): 70 ± 10 vs. 68 ± 7 % (5 μM 
U0126); p = 0.4268; L7/Pcp-2: hCDR2/2L+(PS4): 
65 ± 3 vs. 64 ± 2 % (5 μM U0126), p = 0.5249; 
nE = 4; Fig. 8j).
These data suggest that the MAP kinase signaling cas-
cade is not involved in the CB or L7/Pcp-2 immunoreactiv-
ity reduction induced by hCDR2/2L.
Discussion
CDR antibodies, also known as onconeuronal Yo antibod-
ies, have attracted increasing interest due to their suggested 
pathological role in the progressive loss of PCs seen in 
PCD after binding to CDR2 and CDR2L antigens [22, 31, 
33, 70]. Because the mechanisms underlying PCD, in par-
ticular the effects of CDR antibodies, are largely unknown, 
we investigated whether they are internalized into PCs and 
how that affects PC physiology.
a b d
c e
Fig. 6  Indirect blockage of VGCC via AMPA receptor blockage 
attenuated rCDR-induced pathology. a z-stack multiphoton micro-
graph: indirect blockage of VGCC activity by blocking AMPAR 
activity with CNQX inhibits the observed hCDR2/2L+(PS3)-induced 
loss of CB (magenta) and L7/Pcp-2 (green) (right vs. left panel) 
(hCDR2/2L +(PS3): 4 μL/mL, CNQX: 10 μM; sample: day 6); scale 
bars 40 μm. Stereological counting of CB+ (b, d) and L7/Pcp-2+ 
(c, e) PCs showed that CNQX co-treatment reduced the hCDR2/2L- 
(4 μL/mL; CNQX: 5, 10, 25 μM; PS3: nE = 6; PS4: nE = 4) or 
rCDR-induced pathology (125 ng/mL, 10 μM, nE = 6) in a concen-
tration-dependent manner and more beneficially for rCDR2L than 
rCDR2 (CB: **p = 0.0071; L7/Pcp-2: **p = 0.0011). Data are 
mean ± SEM. Non-parametric two-tailed paired Mann–Whitney’s U 
test. *p < 0.05; **p < 0.01; ***p < 0.001; #p < 0.005; Table 1: CDR 
antibody effects in percentage
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Fig. 7  Protein kinase C gamma expression is up-regulated by CDR2 
and CDR2/2L-Ab internalization. a Representative Western blot: 
PKCγ expression after rCDR internalization. b PKCγ expression 
was significantly increased after CDR2 and CDR2/2L internalization 
(125 ng/mL; 6 days;  nE = 14). c Multiphoton micrographs demon-
strate that the hCDR2/2L+(PS3)-induced loss of CB (magenta) and L7/
Pcp-2 (green) was minimized by PKCγ antagonist K252a (50 nM) 
co-treatment; scale bars 40 μm. Stereological counting of CB+ and 
L7/Pcp-2+ PCs in the obtained micrographs supported the positive 
effect of K252a on CDR antibody-induced pathology by showing 
a loss of <10 % compared to control (hCDR2/2L+(PS3) [4 μL/mL] 
d CB: nE = 4; e L7/Pcp-2: nE = 4; f rCDR2 and rCDR2L [125 ng/
mL] CB: nE = 6; L7/Pcp-2: nE = 6). g Representative Western blot: 
PKCγ expression after rCDR/K252a co-treatment. h K252a co-treat-
ment reduces the rCDR-induced PKCγ expression rise in the rCDR2 
and rCDR2/2L group (125 ng/mL; nE = 5) after K252a co-treat-
ment. Investigated samples: 6 days of CDR internalization; data in 
mean ± SEM; non-parametric two-tailed paired Mann–Whitney’s U 
test. *p < 0.05; **p < 0.01; ***p < 0.001; #p < 0.003; Table 1: CDR 
antibody effects in percentage
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Fig. 8  Calpain-2 activity is increased by CDR-Ab internalization, but 
not MAP kinase. a Representative Western blot: calpain-1 and calpain-2 
expression after rCDR internalization and MDL28170 co-treatment 
(h). b Bar plots show that calpain-1 expression is not affected, but c 
calpain-2 expression is significantly increased after rCDR internaliza-
tion (125 ng/mL; D6; nE = 21) and can be i blocked by co-treatment 
with calpain antagonist MDL28170 (125 ng/mL + 10 μM MDL28170; 
nE = 5). Calpain antagonist MDL28170 reduced the CDR-induced 
CB+ and L7/Pcp-2+ PC loss. d z-Stack multiphoton micrographs: co-
treatment with calpain antagonist MDL28170 (10 μM) beneficially 
affects PC anti-CB (magenta) staining after hCDR2/2L+(PS3) inter-
nalization (4 μL/mL, 6 days); scale bars 40 μm. Stereological count-
ing of CB+ (e) and L7/Pcp-2+ (f) cells/mm3 in these micrographs 
showed that hCDR2/2L+(PS3)/MDL28170 treatment (5, 10, 20 μM) 
reduced the CDR-induced loss of CB [nE = 6 (PS3) and nE = 4 (PS4)] 
and L7/Pcp-2 [nE = 3 (PS4)]. g Similar observation was found for 
rCDR/MDL28170 co-treatment (125 ng/mL, 10 μM MDL28170, CB: 
nE = 5). Calpain antagonist reduced the CDR-induced loss depending 
on the CDR target to up to 60 % (Table 1). This was most pronounced 
for CDR2. j MAP kinase antagonist U0126 (5 μM) does not influence 
the loss of CB+ or L7/Pcp-2+ PCs after hCDR2/2L+(PS3) internaliza-
tion (1 μL/mL; 6 days; nE = 4). Data are mean ± SEM. Non-paramet-
ric two-tailed paired Mann–Whitney’s U test. *p < 0.05; **p < 0.01; 
***p < 0.001; #p < 0.008. Table 1: CDR antibody effects in percentage
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Antibody-mediated PCD model: cerebellar organotypic 
slice culture (cOTSC)
OTSC can be used to study neurochemical, structural, and 
physiological changes linked to diseased in vivo brains [13, 
44]. Hence, we created an ex vivo antibody-mediated PCD 
model by applying CDR-positive patients’ sera and affin-
ity-purified rabbit CDRs to the culture medium of cerebel-
lar rat OTSC. These slices offer unique advantages because 
the tissue architecture is preserved, synaptic circuitries are 
maintained, and various treatments can be evaluated with-
out the influence of activated immune cells and the blood–
brain barrier (BBB) [13, 21, 42–44]. The mechanisms of 
autoimmunity in paraneoplastic neurological diseases are 
complex and not yet understood. It is suggested that brain 
epitope-specific serum Abs can access the brain only if 
the integrity of the BBB is compromised [18, 20]. How-
ever, brain epitope-specific cerebrospinal fluid Abs can be 
produced by intrathecal synthesis due to activated T and 
B cells that can cross the BBB [51, 62]. Data from anti-
Yo/CDR2-Ab positive PCD patients are contradictory in 
terms of cytotoxic T cell involvement [2, 3, 10, 56, 61, 65]. 
Therefore, it is of interest that PCs can internalize IgGs and 
that anti-Yo Abs can lead to cell injury and non-apoptotic 
death without the influence of activated immune cells [31, 
33].
Here, we demonstrate that both hCDR and rCDR can 
cause similar PC pathology. By using rCDR we exclude 
cytotoxic T cell involvement, since the cOTSC was not 
exposed to related peptides which could activate brain-
naive resident T cells [42]. Therefore, our data are most 
likely immune cell independent. We found that both CDR2 
Fig. 9  Cell Ca2+ homeostasis regulating signaling pathways influ-
enced by CDR antibody internalization in Purkinje cells. The flow-
chart clarifies how the cell Ca2+ homeostasis is affected by CDR2 
and CDR2L antibody internalization. In our CDR antibody-mediated 
PCD model, we found that (1) CDR2 interacts with calbindin D28K, 
(2) both CDR2 and CDR2L antibodies attenuate the Ca2+-buffering 
activity of calbindin D28K, (3) modify the VGCC modulator L7/Pcp-
2, and (4) cause increase protein levels of VGCC and PKC. These 
events dramatically increase the levels of unbound cytoplasmic 
Ca2+ to the millimolar range and thereby induce over-activation of 
calpain-2. (5) It is known that calpain over-activation causes rapid 
modifications of synaptic membrane-associated proteins (VGCC, 
AMPAR), cytoskeleton proteins, major postsynaptic density scaffold-
ing proteins, and synaptic protein kinases (PKC) and phosphatases. 
To prevent the enhanced Ca2+ influx through VGCC and free the 
CB binding capability by lowering the unbound cytoplasmic Ca2+ 
could be a putative neuroprotective treatment strategy. Antagonists to 
VGCC (ω-agatoxin), AMPA receptor (CNQX), PKCγ (K252a) and 
calpain (MDL28170) showed satisfactory neuroprotective impacts. 
Our data suggest that CDR2 are more likely interacting with cytosolic 
components and therefore responsible for calpain activation (K252a 
and MDL28170 treatment), whereas CDR2L are more likely to mod-
ify the postsynaptic density structure and physiology (ω-agatoxin and 
CNQX treatment). Therefore, both CDR antibodies can cause fatal 
alterations in the Purkinje cell signaling pathways and membrane 
structures by affecting actin remodeling, membrane reorganization, 
and protein trafficking, thereby cause neurodegeneration
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and CDR2L are internalized independently and their 
removal can partly reverse the calpain-2-dependent, but 
caspase-3-independent, pathology. We found equal effects 
of CDR2 and CDR2L on PC survival, although only a com-
bination of CDR2/2L is associated with PCD [22]. How-
ever, CDR2/2L pathology was stronger, e.g., PKCγ results, 
and reciprocal Co-IP showed a CDR2–CDR2L complex 
in PCs, which supports the hypothesis that increased 
Ab avidity enhances the pathological effects [71]. Our 
CDR-induced pathology followed a similar time frame as 
described by Greenlee and colleagues [31], but the CDR 
internalization mechanisms remain to be explored. A recent 
study by Congdon et al. [14] demonstrated antibody inter-
nalization via IgG-FcγII receptor endocytosis. IgG-FcγII 
receptors are found in PC and regulate cerebellar function 
[47].
CDR internalization affects postsynaptic signaling 
and thereby Ca2+ homeostasis: AMPAR–VGCC–PKC–
calpain
In Fig. 9 we show the complexity, by which h/rCDR inter-
nalization changes PC physiology by targeting postsynaptic 
signaling factors and thereby modifies Ca2+ homeostasis. 
We described these factors along with related neurological 
diseases in Table S1. We found that the immunoreactivity 
of Ca2+ homeostasis regulator CB and VGCC modula-
tor L7/Pcp-2 was reduced. These proteins are function-
ally linked, since CB shapes the post-tetanic potentiation 
induced by the Ca2+ influx through AMPAR and VGCC 
and can act as an activity-dependent sensor [32, 57]. When 
endogenous CB levels are reduced, PC dendritic outgrowth 
and differentiation is inhibited, and motor coordination 
and sensory integration fail [1, 4, 37, 74]. We found that 
the total CB protein levels are not affected by CDR inter-
nalization. However, Co-IP reveals that CDR2–CB forms a 
strong protein complex and therefore CDR2 antibody bind-
ing to CDR2 protein in the cell may disrupt CB function 
by sequestering CDR2 and thus hijacking CB’s interacting 
partner. “CDR antibody washout” restored the CB immu-
noreactivity only partially, indicating irreversible modifica-
tions of the CB Ca2+-binding mechanism or protein struc-
ture, as seen in other neurodegenerative diseases [11, 50].
CB dysfunction or deletion can result in drastic fast 
intracellular Ca2+-transient elevation which greatly influ-
ences Ca2+ homeostasis [4]. In PC signaling, intracellu-
lar Ca2+ microdomain variations due to AMPAR, VGCC, 
or PKC activity play a crucial role [24, 27, 34, 57, 68]. 
AMPAR activation by glutamate binding and site-specific 
PKC and receptor tyrosine kinases’ phosphorylation pro-
vides the depolarization necessary for opening VGCCs 
and therefore increases Ca2+ influx [19, 32, 57, 73]. 
We found that the P/Q-type VGCC modulator L7/Pcp-2 
immunoreactivity is reduced and Cav2.1 (P/Q-type VGCC) 
protein concentration is increased by twofold after CDR 
internalization. L7/Pcp-2 modulates VGCC function in a 
concentration-dependent manner and enhances or damp-
ens VGCC kinetics to shape fast Ca2+ influx in synaptic 
Ca2+ microdomains [39]. Inhibiting VGCC activity directly 
(ω-agatoxin) or indirectly (CNQX) prevented or reduced 
dramatically the CDR-induced CB and L7/Pcp-2 loss, 
respectively. CDR2L-induced pathology was more effec-
tively reversed than CDR2 during AMPAR inhibition. Data 
from primary PC culture and synaptoneurosome prepara-
tion (data not shown) support that CDR2L is synaptic and 
could thereby be involved in membrane-associated sign-
aling cascades. CB and L7/Pcp-2 dysfunction and VGCC 
up-regulation will promote excessive Ca2+ influx into PCs, 
which can activate cell death pathways by enhancing PKC 
and Ca2+-dependent protease activity [41].
PKC is associated with apoptosis in ischemia and stroke 
[8, 29, 60]. In PCs, enhanced PKC activity will reduce 
dendritic differentiation, whereas reduced PKC activity 
increases it [45, 46]. We found that the up-regulation of 
PKCγ expression under CDR internalization was accom-
panied by reduced dendritic arborizations and loss of ter-
tiary branches. In retina, L7/Pcp-2 interacts with PKC 
[64] and we found that the increased PKC activity led to 
reduced L7/Pcp-2 expression (data not shown). Inhibition 
of PKCγ activity prevented the CDR-induced morphologi-
cal changes, the loss of CB as well as L7/Pcp-2 immuno-
reactivity and blocked the increased PKCγ protein expres-
sion. However, the increase in PKCγ expression was only 
seen for CDR2 and CDR2/2L, but not for CDR2L inter-
nalization, although K252a rescued the CB and L7/Pcp-2 
immunoreactivity in all rCDR-treated cOTSCs. We there-
fore hypothesize that CDR internalization enhances PKC 
activity, which: first, reduces L7/Pcp-2 expression; second, 
increases Cav2.1 expression; third, increases intracellu-
lar Ca2+, which activates Ca2+-dependent proteases such 
as calpain-1 and calpain-2 and thereby induces neuronal 
death.
Calpain-1 and calpain-2 are activated by different cel-
lular Ca2+ concentrations. In Alzheimer’s, Huntington’s, 
and Parkinson’s disease, calpain over-activation or dys-
regulation triggers neuronal death by truncation of impor-
tant synaptic substrates [5, 16, 17, 26, 53, 59]. Western blot 
analysis revealed that CDR internalization significantly 
increased calpain-2 protein expression, but not calpain-1 
which indicates a intracellular Ca2+ level above 0.250 mM 
[75]. Inhibiting calpain activity by calpain antagonist 
MDL28170 reduced the CDR-induced CB loss and blocked 
calpain-2 protein enhancement. Interestingly, the CDR2L 
induced pathology is less affected by calpain inhibition 
than CDR2. This may be explained by the distribution of 
CDR2 (cytosol) and CDR2L (membrane) proteins [22]. 
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We hypothesize that CDR internalization affects activity-
dependent modifications of synaptic integrity, stability, and 
function of target proteins, which modulates the synaptic 
Ca2+ transient by mediating over-activation of calpain-2 [5, 
17]. As calpain-mediated truncation of substrates is regu-
lated by their phosphorylation state, there is a possibility 
of cross talk between calpain activation and activation of 
mitogen-activated protein (MAP) kinase. MAP kinase sign-
aling cascades are associated with PKC-dependent synap-
tic depression and declustering of receptors, inflammation, 
death receptors’ activation, apoptosis, and oxidative stress 
[12, 23, 35]. Althought PKC inhibition prevented CDR-
induced CB and L7/Pcp-2 loss, blockage of MAP kinase 
activity did not show any rescue effects.
Conclusion
PCD pathogenesis is largely unknown. We propose a two-
step pathology mechanism. First, internalization of CDR 
antibodies modifies important regulatory factors of Ca2+ 
homeostasis, which lead to the silencing of the PCs. Sec-
ond, cytototoxic T cells and microglia mediate the clearing 
of diseased cells, as known from autopsy studies [61].
CDR antibodies play an important role in the PCD 
pathogenesis by inducing PC loss, which causes severe 
ataxia, dysarthria, diplopia, and vertigo in PCD patients. 
In line with previous results, we have shown that such cer-
ebellar findings can be linked to imbalance in intracellu-
lar Ca2+ homeostasis due to alterations of CB, VGCC, or 
PKC [1, 27, 40, 58, 69]. Therefore, lowering the intracel-
lular Ca2+ levels by inhibition, the VGCC–AMPAR–PKC 
signaling pathway (Fig. 9) during the progress of PCD will 
beneficially modulate Ca2+ homeostasis by stabilizing the 
Ca2+-binding capability of CB and prevent the induction of 
the critical calpain response cascade. The strong neuropro-
tective effect of antagonizing VGCC–AMPAR–PKC sign-
aling pathway during CDR antibody internalization may 
therefore be of potential clinical relevance.
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